DCF Advisers LLC Has $962,000 Holdings in Teladoc Health, Inc. $TDOC

DCF Advisers LLC increased its stake in shares of Teladoc Health, Inc. (NYSE:TDOC) by 292.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 137,500 shares of the health services provider’s stock after purchasing an additional 102,500 shares during the period. DCF Advisers LLC’s holdings in Teladoc Health were worth $962,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. IFP Advisors Inc grew its stake in shares of Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock worth $31,000 after purchasing an additional 3,210 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Teladoc Health by 177.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after purchasing an additional 2,810 shares during the period. Aster Capital Management DIFC Ltd raised its holdings in Teladoc Health by 101.1% in the third quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock worth $37,000 after purchasing an additional 2,425 shares during the period. International Assets Investment Management LLC acquired a new stake in Teladoc Health in the fourth quarter worth $45,000. Finally, KBC Group NV raised its holdings in Teladoc Health by 88.3% in the fourth quarter. KBC Group NV now owns 9,632 shares of the health services provider’s stock worth $67,000 after purchasing an additional 4,516 shares during the period. 76.82% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Teladoc Health

In related news, insider Fernando M. Rodrigues sold 5,677 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $43,315.51. Following the completion of the transaction, the insider owned 9,572 shares in the company, valued at approximately $73,034.36. This represents a 37.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $145,977.16. Following the transaction, the chief executive officer owned 389,894 shares of the company’s stock, valued at $2,974,891.22. The trade was a 4.68% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 39,870 shares of company stock worth $302,507. Company insiders own 0.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on TDOC shares. Stifel Nicolaus cut their target price on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Thursday, February 26th. BMO Capital Markets cut their target price on shares of Teladoc Health from $8.00 to $5.00 and set a “market perform” rating on the stock in a report on Thursday, February 26th. Canaccord Genuity Group cut their target price on shares of Teladoc Health from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Weiss Ratings upgraded shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, Bank of America upgraded shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.43.

Teladoc Health Stock Performance

TDOC opened at $7.10 on Thursday. The business’s 50-day moving average price is $6.30 and its two-hundred day moving average price is $6.22. Teladoc Health, Inc. has a 1 year low of $4.40 and a 1 year high of $9.77. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -7.32 and a beta of 2.14. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The firm had revenue of $613.85 million during the quarter, compared to analyst estimates of $611.04 million. During the same period in the prior year, the business earned ($0.53) EPS. The business’s revenue for the quarter was down 2.5% compared to the same quarter last year. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. Equities analysts expect that Teladoc Health, Inc. will post -0.92 EPS for the current fiscal year.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.